

FOOD ADVISORY COMMITTEE and DIETARY SUPPLEMENTS SUBCOMMITTEE

**GLUCOSAMINE AND CHONDROITIN SULFATE
AND OSTEOARTHRITIS**

June 7-8, 2004

Tentative Agenda¹

June 7, 2004 - Monday

- 8:00 Welcome and Member Introduction
Dr. Sanford A. Miller
Chairman, Food Advisory Committee (FAC)
- 8:20 Conflict of Interest Statement
Linda Reed
Acting Executive Secretary, FAC
- 8:30 Opening Remarks
Dr. Robert E. Brackett
Director, Center for Food Safety and Applied Nutrition (CFSAN)
- 8:35 Background and Questions to Committee
Dr. Barbara O. Schneeman
Director, Office of Nutritional Products, Labeling, and Dietary Supplements,
(ONPLDS)/CFSAN
- 8:45 Questions and Clarification
- 8:50 Overview of Legal Framework
Louisa Nickerson, Office of General Counsel/FDA
- 9:05 Questions and Clarification
- 9:10 Overview of Petitions: FDA's Review Process and Issues
Dr. Craig Rowlands, Biologist, FDA/ONPLDS/CFSAN
- 9:40 Questions and Clarification
- 10:05 Break
- 10:20 Petitioner: Weider Nutrition International, Inc
Dr. Luke R. Bucci, Vice President of Research, Weider Nutrition Group
- 11:05 Questions and Clarifications

¹ The times indicated on this tentative agenda are approximations. Breaks will also be called as deemed appropriate by the Chairman.

11:20 Petitioner: Rotta Pharmaceutical, Inc
Dr. Roy D. Altman, Professor of Medicine and Rheumatology, University of Miami
and University of California-Los Angeles

Dr. Lucio C. Rovati, Executive Medical Director, Rotta Research Laboratory

12:05 Questions and Clarifications

12:20 Lunch

1:35 Current State of the Science on Etiology of OA and Modifiable Risk Factors for OA
Dr. Lee Simon, Harvard University

2:20 Questions and Clarifications

2:25 The Role of Animal and in vitro Models in OA Risk Reduction
Dr. James Witter, Center for Drug Evaluation and Research/FDA

2:55 Questions and Clarification

3:10 Break

3:25 Public Comment

4:50 Questions and Clarification

5:00 Adjourn

June 8, 2004 - Tuesday

8:00 Call to Order, Review of Charge and Questions
Committee Chair

8:15 Review of Issues
Dr. Craig Rowlands, FDA/ONPLDS/CFSAN

8:35 Questions and Clarifications

8:40 Committee Discussion

10:00 Break

10:15 Committee Discussion (Continued)

11:30 Lunch

12:30 Concluding Deliberations, Recommendations, Response to Charges and Vote

1:30 Concluding Comments
Committee Chair

1:45 Meeting Adjourns